...
Does Dupilumab Affect Vaccine Response?
January 22, 2019

Patients with moderate-to-severe atopic dermatitis have shown improvement when treated with dupilumab, a monoclonal antibody that targets the IL-4 receptor a subunit, which inhibits signaling of both IL-4 and IL-13. There are many immune factors that contribute to immune response, but a recent study sought to determine whether dupilumab might affect patients’ responses to commonly

...
SDPA Fall 2018 | Dupixent (dupilumab)
November 3, 2018

On day two of the 16th Annual Fall Conference, Cynthia Trickett, MPAS, PA-C, DFAAPA shared her clinical insights regarding the treatment of atopic dermatitis (AD) in her lecture on Dupixent. AD is estimated to affect 3.2% of adults in the US and around 1.6 million with moderate to severe AD remain uncontrolled despite treatment. Ms.